Roche announced Mark Dawson, M.D., Ph.D., will lead Roche Pharma Research and Early Development (pRED) starting May 1, 2026. Dawson is a distinguished physician-scientist with extensive experience in cancer biology. He joins Roche from the Peter MacCallum Cancer Centre where he served as Associate Director of Research. His research focuses on chromatin regulation and epigenetics, crucial for understanding cancer. Dawson also holds a professorial appointment at the University of Melbourne. He is recognized by multiple scientific academies in Australia and Europe. Dawson's accolades include the Prime Minister’s Prize for Science and the Paul Marks Prize for Cancer Research. His background as a clinician-researcher is expected to drive innovation at Roche pRED. Roche, founded in 1896, is a global leader in biotechnology and diagnostics, committed to personalized healthcare.